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GuidelinesAldosterone is involved in various deleterious effects on the cardiovascular system, including sodium and ﬂuid
retention,myocardialﬁbrosis, vascular stiffening, endothelial dysfunction, catecholamine release and stimulation
of cardiac arrhythmias. Therefore, aldosterone receptor blockade may have several potential beneﬁts in patients
with cardiovascular disease. Mineralocorticoid receptor antagonists (MRAs) have been shown to prevent many
of the maladaptive effects of aldosterone, in particular among patients with heart failure (HF). Randomized con-
trolled trials have demonstrated efﬁcacy of MRA in heart failure with reduced ejection fraction, both in patients
with NYHA functional classes III and IV and in asymptomatic and mildly symptomatic patients (NYHA classes I
and II). Recent data in patients with heart failure with preserved ejection fraction are encouraging. MRA could
also have anti-arrhythmic effects on atrial and ventricular arrhythmias and may be helpful in patient ischemic
heart disease through prevention of myocardial ﬁbrosis and vascular damage. This article aims to discuss the
pathophysiological effects of aldosterone in patients with cardiovascular disease and to review the current
data that support the use of MRA in heart failure.
© 2014 TheAuthors. Published by Elsevier Ireland Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Aldosterone in the pathophysiology of heart failure
Aldosterone is a mineralocorticoid hormone produced in response
to angiotensin II release, hyperkalemia, and corticotropin mainly by
the adrenal cortex. In addition to this pathway, recent evidences suggest
local, extra-adrenal production of aldosterone by endothelial cells and
vascular smoothmuscle cells in the blood vessels andmyocardium [1,2].
Aldosterone binding to mineralocorticoid receptor results in reab-
sorption of sodium and water in exchange for potassium in various
sites including the distal tubule and collecting duct of the nephron,
causing an increased intravascular ﬂuid retention and volume overload.
In addition to these classical epithelial effects, aldosterone has a variety
of negative non-epithelial effects including induction of inﬂammation,
vascular stiffening, collagen formation, myocardial necrosis and stimu-
lation of ﬁbrosis [1].
Aldosterone has an important role in the pathogenesis of heart
failure. Increased levels of aldosterone tend to promote myocardial
hypertrophy and remodeling, induce ﬁbrosis and apoptosis, contribute
to endothelial dysfunction and reduce myocardial perfusion, thus
increasing the incidence of cardiovascular events [3]. In patients with9 303996801.
land Ltd. This is an open access articleHF, plasma aldosterone may reach levels of 300 ng/dL, which is up to
60-fold the levels measured in normal subjects (5–15 ng/dL) [1].
Aldosterone has well-known effects in sodium and ﬂuid retention
that could account for an undesired impact in ﬂuid balance in patients
with CHF, causing hypervolemia and promoting congestion. In addition
to its role in sodium balance, aldosterone stimulates cardiac ﬁbrosis,
which is one of the principal mechanisms involved in cardiac remodel-
ing and progression of heart failure. In experimentalmodels stimulation
of mineralocorticoid receptor has been found to increase cardiac levels
of the matrix cellular protein osteopontin, leading to increased ﬁbrosis,
and diastolic dysfunction [4].
Other studies have shown an increase of collagen and ﬁbrosis
in myocardial tissue in subjects treated with aldosterone [5–7].
Mechanisms at the basis of this action are various. Lijnen et al. proposed
an involvement of angiotensin II acting through up-regulation of angio-
tensin receptor subtype 1 induced by aldosterone [8]. At a molecular
level, Nakamura et al. demonstrated a critical role of apoptosis signal-
regulating kinase 1 (ASK1) in the mechanism underlying aldosterone-
induced cardiac injury. ASK1 is implicated in aldosterone/salt-induced
cardiac inﬂammation and ﬁbrosis through the enhancement of NADPH
oxidase-mediated oxidative stress and the up-regulation of the cardiac
renin–angiotensin system [9]. Aldosterone also enhances the gene ex-
pression of proﬁbrotic molecules, including collagen, transforming
growth factor-beta (TGF-beta) and plasminogen activator inhibitor,under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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effects, which involve transactivation of the epithelial growth-factor
receptor (EGFR) and the phosphorylation of extracellular-signal-
regulated kinase 1 (ERK)1/ERK2, thereby up-regulating the expression
of pro-inﬂammatory transcription factors and related molecules. In the
myocardium and in the kidney, the net effect of aldosterone-induced
inﬂammation and extracellular matrix accumulation is tissue ﬁbrosis
and, ultimately, myocardial and renal scarring [10].
Another consequence of aldosterone/MR activation and cardiac
remodeling is electrical remodeling. Myocardial ﬁbrosis induced by
aldosterone has an arrhythmogenic role in heart failure [11–13]. Some
studies conﬁrm that aldosterone and MR activation have also direct
effects on cardiomyocyte calcium-handling that may predispose to
arrhythmias [14].
Aldosterone is also involved in endothelial dysfunction, mainly by
decreasing the bioavailability of nitric oxide and promoting oxidative
stress [16].
Other negative effects of aldosterone are activation of the sympathetic
nervous system, reduction of baroreceptor sensitivity, and activation of
myocyte apoptosis [2].
Given these assumptions, it is clear that aldosterone receptor
blockade could be beneﬁcial in patients with cardiovascular disease in
a variety of ways. Aldosterone receptor antagonists have been shown
to preventmany of themaladaptive effects of aldosterone on the cardio-
vascular system. For instance, spironolactone prevents the aldosterone-
mediated collagen synthesis that contributes to adverse left ventricular
remodeling [7]. Rats with post-infarction heart failure treated with
aldosterone receptor antagonists have improved left ventricular (LV)
diastolic and systolic functions, a reduction of reactive ﬁbrosis, and
reduced myocardial norepinephrine content [17]. Eplerenone inhibits
superoxide formation and enhances nitric oxide-dependent relaxation
in experimental studies [18].
2. Aldosterone receptor antagonists
2.1. Spironolactone
Spironolactone is a widely used, non-selective aldosterone receptor
antagonist marketed since the early 60s that is metabolized extensively
in the liver to its activemetabolites. Its plasma half-life is 1.4 h, although
in CHF patients with hepatic congestion, this duration may increase
5-fold. A maximal drug response is seen 48 h after the ﬁrst dose.
Spironolactone is structurally similar to progesterone, thereby allowing
sex-steroid receptor cross-reactivity. This phenomenon accounts for the
anti-progesterone and anti-androgen effects observed in some patients
treated with spironolactone. Gynecomastia or breast pain is the
most frequent side-effect of spironolactone, occurring in about 10% of
patients in chronic treatment [19].
2.2. Canrenone
Canrenone is the principal active metabolite of spironolactone,
devoid of ﬁrst-pass effect, and has a long half-life (of 16.5 h). As
spironolactone, canrenone is a non-selective MRA, but a lower inci-
dence of anti-androgen side effects has been reported [20]. It is fre-
quently used as an alternative to spironolactone mainly in European
countries. Canrenone is also derived from the rapid conversion in vivo
of the salt potassium canrenoate, which has shown important anti-
remodeling effects in post-infarction LV remodeling [21].
2.3. Eplerenone
Eplerenone is a selective aldosterone receptor antagonist derived
from spironolactone but with lower afﬁnity for the progesterone
and androgen receptors so it lacks sex-related adverse side effects.
Eplerenone is metabolized in the liver by cytochrome P450 (isoenzymeCYP3A4); plasma levels of eplerenone are inﬂuenced by concomitant
use of inhibitors of CYP3A4, including ketoconazole, itraconazole,
ribonavir, and clarithromycin, that are associated with signiﬁcant
increases in its peak levels, whereas inducers of CYP3A4 such as pheno-
barbital decrease it. Eplerenone has a plasma half-life of 4 to 6 h, and
steady-state drug levels are usually achieved 48 h after the ﬁrst dose.
2.4. Side effects
A serious class side effect of MRAs is represented by hyperkalemia.
Aldosterone, by binding its receptor, stimulates the apical Na–K-ATPase
pump and luminal potassium channel activity into the late distal convo-
luted tubules and the distal collecting ducts, thus promoting luminal
potassium excretion. Therefore, antagonism of the aldosterone receptor
decreases luminal K excretion, promoting accretion of potassium in
the body. When severe, hyperkalemia may precipitate cardiomyocyte
membrane potential destabilization and unstable ventricular arrhyth-
mias [17]. Although serious hyperkalemia occurred in about 2–3% of
MRA treated patients in randomized clinical trial, [19,22] rates as high
as 10% in the community have been reported [18]. The risk of serious
hyperkalemia is minimized by routine serum potassium and renal
function monitoring, and avoidance of concurrent pharmacotherapies
associated with potassium retention or diet and dietary supplements
containing high levels of potassium. Of particular interest, a novel ther-
apeutic agent called RLY5016 (oral, a non-absorbed, potassium-binding
polymer) prevented hyperkalemia in patients with HF receiving stan-
dard therapy and spironolactone [23].
Other important side-effects are linked to spironolactone cross-
reaction with androgen-receptors. The incidence of spironolactone-
associated breast tenderness and gynecomastia reported in clinical
trials is 6.9% to 10% for men and typically occurs at doses 50 mg/d [19].
Generally, these side effects resolve with drug cessation. Spironolactone
may also lower testosterone levels, causing erectile dysfunction in
male and menstrual irregularities in female; when present, these
side effects increase rates of medication noncompliance [7]. In contrast
to spironolactone, eplerenone has 100–1000 lower afﬁnity to testoster-
one and progesterone receptors, meaning less pronounced, placebo-
equivalent, sexual side effects [22].
2.5. Future research on aldosterone antagonists and synthase inhibitors
There is an active research for novel aldosterone antagonists with
similar potency as spironolactone and even higher speciﬁcity than
eplerenone such as SM-368229 from Dainippon Sumitomo Pharma
Co., Ltd. (Osaka, Japan) [24]. A novel approach is to move from receptor
blockade to the inhibition of aldosterone synthesis [25]. At least three
compounds with this mechanism of action were identiﬁed: FAD286
(Novartis, Basel, Switzerland), LCI699 (Novartis, Basel, Switzerland)
and SPP2745 (Novartis, Basel, Switzerland) [26]. FAD286, an enantio-
mer of fadrazole with an inhibitory effect on aldosterone synthase, has
been shown to reduce blood pressure, attenuate myocardial and renal
injury [27,28] andnormalize redox status in rats aftermyocardial infarc-
tion [29]. SPP2745 suppressed aldosterone levels and also provided car-
diac, renal and vascular protective effects when administered on top of
conventional therapy [26]. Finally, LCI699 suppressed aldosterone levels
and lowered blood pressure by 4.1 mmHg in 14 hypertensive patients,
but also latently inhibited cortisone formation [30]. Inhibition of
aldosterone synthase should prevent reactive increase in aldosterone
levels and adverse androgen receptor-related effects, since these new
drugs do not have a steroid structure. On the other hand, mineralocorti-
coid receptors are also stimulated by cortisol and other ligands that are
released in conditions of augmented oxidative stress [31]. Aldosterone
synthase inhibitors will not oppose these aldosterone-independent
mechanisms that might be blocked by spironolactone or eplerenone.
Future studies will show whether what these theoretical concerns will
have as clinical implications.
Table 1
Effects of MRA therapy on LV remodeling, NYHA class and diastolic function in patients with heart failure and reduced ejection fraction.
LVEF (left ventricular ejection fraction), LVESVI (left ventricular end-systolic volume index), LVEDVI (left ventricular end-diastolic volume index), E (peak velocities of early mitral inﬂow), DT (E wave deceleration time). WMD indicates weighted
mean difference.
Author Time LVEF (%) (WMD) NYHA functional class
(WMD)
LVESVI (mL/mq) (WMD) LVEDVI (mL/mq) (WMD) E (cm/s) (WMD) DT (ms) (WMD)
Barr et al. [95] 8 weeks 20 ± 6→ 19 ± 6
(P = NS)
– – – 57 ± 4→ 51 ± 6
(P = NS)
–
Tsutamoto et al. [96] 4 months 32.2 ± 2.2→ 35.0 ± 1.9
(P b 0.05)
2.3 ± 0.1→ 1.9 ± 0.1
(P = 0.002)
– 192 ± 11→ 178 ± 10 (P b 0.05) – –
Cicoira et al. [97] 12 months 33 ± 7→ 36 ± 9 (P b 0.01) – 188 ± 94→ 171 ± 97 (P b 0.01)
(not indexed)
275 ± 104→ 251 ± 105
(P b 0.01) (not indexed)
62 ± 21→ 59 ± 21
(P = NS)
217 ± 93→ 219 ± 67 (P = NS)
Akbulut et al. [98] 12 weeks 28.9 ± 6.1→ 36.3 ± 8.3
(P b 0.01)
– – – – –
Kasama et al. [88] 6 months 33 ± 6→ 39 ± 6
(P b 0.005)
2.8 ± 0.4→ 1.7 ± 0.5
(P b 0.0005)
– 187 ± 26→ 154 ± 41 (P b 0.005)
(not indexed)
– –
Ozkara et al. [99] –
Kasama et al. [100] 6 months 32 ± 6→ 43 ± 11
(P b 0.001)
2.6 ± 0.5→ 1.9 ± 0.7 (P b 0.001) 131 ± 30→ 95 ± 29 (P b 0.001)
(not indexed)
192 ± 32→ 165 ± 30 (P b 0.001)
(not indexed)
– –
Gao et al. [86] 6 months 42 ± 11→ 46 ± 13 – – – – –
Chan et al. [47] 52 weeks 26 ± 2→ 35 ± 3 (P b 0.01) 2.0 ± 0.6→ 1.5 ± 0.5
(P b 0.001)
120.30 ± 14.74→ 88.14 ± 17.10
(P b 0.01)
154.68 ± 14.21→ 121.10 ± 15.76
(P b 0.01)
77 ± 6→ 62 ± 4
(P b 0.05)
216.87 ± 21.81→ 251.89 ± 15.71
(P = NS)
Boccanelli et al. [20] 12 months 39.9 ± 8.6→ 45.1 ± 9.6
(P b 0.05)
– – 156.8 ± 54.5→ 128.2 ± 44.6
(P b 0.05) (not indexed)
– –
Taheri et al. [101] 6 months 31.3 ± 8.8→ 41.2 ± 9.6
(P = 0.01)
– – – – –
Udelson et al. [46] 36 weeks P = NS P = NS P = NS P = NS – –
Vizzardi et al. [45] 6 months 34.6 ± 9.8→ 38.4 ± 6.3
(P b 0.001)
– 114.5 ± 5.6→ 96.9 ± 9.0
(P b 0.001) (not indexed)
173.2 ± 28.9→ 155.9 ± 4.2
(P b 0.001) (not indexed)
57 ± 54→ 37 ± 14
(P b 0.001)
236 ± 106→ 273 ± 70
(P = 0.001)
Kimura et al. [102] 12 months 34 ± 6→ 37 ± 8 (P = NS) – – 61 ± 4→ 59 ± 5 (P b 0.05) – –
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3.1. Heart failure with reduced ejection fraction (HF-REF)
As previously discussed, aldosterone is regarded as a potent media-
tor of cardiac remodeling in left ventricular dysfunction and therapy
with MRA has a role in preventing these maladaptive effects in patients
with CHF and left ventricular (LV) systolic dysfunction. A number of
large randomized controlled trials (RCTs) investigating the beneﬁt of
aldosterone antagonists in patients with systolic heart failure have
demonstrated a clear reduction in death and cardiovascular morbidity
[19,22,32], as well as beneﬁts in systolic and diastolic patterns (Table 1).
Three landmark randomized controlled clinical trials have shown
the beneﬁts of MRA therapy with reduction of morbidity and mortality
among patients with reduced LV ejection fraction (LVEF), Table 2. Ran-
domized ALdactone Evaluation Study (RALES) published in 1999 was
the ﬁrst large, randomized, double-blind, placebo-controlled trial on a
mineralocorticoid receptor antagonist in patients with heart failure
(HF) [19]. RALES evaluated the beneﬁts of spironolactone in a total of
1663 patients with severe heart failure (functional class New York
Heart Association III and IV) and decreased LVEF (EF ≤ 35%) who
were being treated with standard therapy for heart failure. Patients
were randomly assigned to receive spironolactone (25–50 mg daily,
mean daily study dose 26 mg) or placebo for a mean follow-up period
of 24 months. The primary end-point was all-cause mortality. Patients
randomized to spironolactone had a signiﬁcantly lower risk of death
from any cause when compared with placebo (35% vs 46%, RR 0.70, P
b 0.001). Spironolactone also reduced cause-speciﬁc mortality. Sudden
death was reduced by 29% and death due to progressive heart failure
was reduced by 36% (RR 0.64). In the spironolactone treated group
hospitalization for worsening heart failure was 35% lower. In addition,
patients who received spironolactone had a signiﬁcant improvement
in their symptoms of heart failure assessed using NYHA functional
class. Safety of spironolactone was acceptable: patients randomized to
spironolactone had an increase in median potassium concentration of
0.3 mEq/L, but the incidence of severe hyperkalemia (serum potassium
≥ 6 mEq/L) in the treatment group was only 2% and not signiﬁcantly
different from placebo group, (P = 0.42). A recent post-hoc analysis
showed that African American (AA) subjects with HF enrolled in
this study exhibited less hyperkalemia and more hypokalemia with
spironolactone compared with non-AAs and seemed to derive less clin-
ical beneﬁt: in non-AA participants, spironolactonewas associatedwith
a 30% reduction in the risk for all-causemortality (adjusted hazard ratio,
0.70) and a 36% reduction in the risk for the composite outcomeof death
or hospitalization for HF (adjusted hazard ratio); in the AA participants,
spironolactone use was associatedwith no effect onmortality (adjusted
hazard ratio, 0.84) or death or hospitalizations for HF (adjusted hazard
ratio, 1.18). These ﬁndings suggest that safety and efﬁcacy of mineralo-
corticoid receptor antagonists may differ by race but mechanisms
underlying this difference are unclear at this moment so further study
will be necessary [33]. Additional insights from RALES suggest that
spironolactone limited the excessive extracellular matrix turnover in
the heart, which may contribute to prevention of adverse cardiac
remodeling in patients with HF [34].
The knowledge about aldosterone as a mediator of myocardial
remodeling and ﬁbrosis is the rationale at the basis of a second impor-
tant trial on patients with LVEF and heart failure, which evaluated
patients with recent acute myocardial infarction: the Eplerenone
Post-myocardial infarction Heart failure Efﬁcacy and Survival Study
(EPHESUS). This trial demonstrated the beneﬁt of aldosterone receptor
antagonists in patients with LVEF b40% after MI. Patients (n = 6642)
included those post-MI who had left ventricular dysfunction and either
diabetes or clinical evidence of HF and they were randomized to
eplerenone 25 mg/d or placebo for 4 weeks, after which the dose of
eplerenone was increased to a maximum of 50 mg/die. Patients were
followed for an average of 16 months. In EPHESUS, MRA therapy
10 E. Vizzardi et al. / IJC Heart & Vessels 3 (2014) 6–14signiﬁcantly reduced mortality and morbidity. Eplerenone reduced
the risk of death from any cause and death for cardiovascular causes
by 15% and 13%, respectively. Eplerenone also reduced time to death
from any cause (RR 0.85, P = 0.008) and the composite of time
to cardiovascular death or ﬁrst cardiovascular hospitalization (RR 0.87,
P = 0.02) when compared with placebo. Serious hyperkalemia
(≥6 mEq/L) was reportedmore often in the eplerenone group. How-
ever, drug discontinuation was similar between the two (4.5% vs 4.4%).
An interesting result in EPHESUS was that the survival advantage with
eplerenone treatment was seen as early as 30 days after initiation of
therapy. In a similar study evaluating MRA therapy on post-infarction
LV remodeling, in patients with ﬁrst acute anterior MI after revascular-
ization, it was found that combination of spironolactone and ACE-
inhibitors prevented post-infarction LV remodeling better than ACE-
inhibitors alone [35].
These ﬁndings are in line with reports that high plasma levels of
aldosterone discovered during hospitalization for an acute ST-segment
elevation myocardial infarction are an independent prognostic marker
for future CHF, ventricular arrhythmia, and cardiac death [36,37].
About Acute HF, the usefulness of aldosterone receptor antagonists
in the setting of acute decompensated heart failure has not been
determined. Current evidence from RALES and EPHESUS supporting
the use of aldosterone receptor antagonists is based on long-term
clinical outcome data, but the acute effects of these agents are less
established. Evidence suggests that aldosterone antagonists may
improve cardiac vagal control (including heart rate variability and
baroreﬂex sensitivity) immediately after intravenous administration,
an effect that may be beneﬁcial in decompensated heart failure and MI
[38].
RALES only evaluated patients with HF in class NYHA classes III to IV.
Recently, evidence from the Eplerenone inMild Patients Hospitalization
and Survival Study in Heart Failure (EMPHASIS-HF) study suggests that
also patients with mild heart failure beneﬁt substantially from aldoste-
rone receptor antagonist therapy [22]. This study enrolled 2737 patients
with NYHA class II systolic heart failure and left ventricular ejection
fraction ≤35% (patients with LVEF N30% but b35% could be included if
QRS complex was N130 ms on ECG) randomly assigned to receive
eplerenone (up to 50 mg daily) or placebo. The addition of eplerenone
to optimal therapy reduced the risk of cardiovascular death or hospital-
ization for HF (18.3% vs 25.9%, HR 0.63, P b 0.001). Beneﬁts of
eplerenone therapy were also observed in several secondary outcomes
including all-cause mortality (HR 0.76, P = 0.008). Focusing on hospi-
talization, post-hoc analyses of the EMPHASIS-HF data suggested that
patients with mild HF and treated with eplerenone had signiﬁcantly
fewer HF hospitalizations especially within the ﬁrst year. In addition,
eplerenone not only reduces the risk of ﬁrst admissions but also
decreases the likelihood of second and subsequent admissions for
heart failure (and, therefore, the overall number of patients hospitalized
and the total number of admissions for any reason) [39]. Eplerenone
was generally well tolerated in EMPHASIS-HF with the most frequent
adverse event being hyperkalemia, but the incidence of severe
hyperkalemia (deﬁned as serum potassium N 6 mEq/L) was not
different among eplerenone and placebo-treated patients (2.5 vs. 1.9%,
P = 0.29). Sexual adverse events (e.g. gynecomastia) occurred in b1%
of eplerenone recipients, reﬂecting the selectivity of eplerenone for
mineralocorticoid receptors. A recent analysis of EMPHASIS-HF con-
ﬁrms that beneﬁts of eplerenone therapy were evident even in the
sub-group of patients receiving high doses of standard background
therapies (ACE-i, or angiotensin receptor blocker, β-blocker, or both
drug classes) [40]. Finally, another recent post-hoc analysis from
EMPHASIS-HF, categorized subjects enrolled in this trial into three
groups of low-, medium-, and high-risk based on strong independent
risk factors identiﬁed using multivariable analysis: age, sex, systolic
blood pressure, estimated glomerular ﬁltration rate, diabetes, BMI,
hemoglobin, prior HF, prior myocardial infarction, and heart rate.
Rates (per 100 patient-years) of the primary outcome in patientstreated with were 7.6, 19.0, and 39.4 in the low, medium and high risk
group, respectively. Among patients treated with eplerenone, these
rates were 5.6, 12.2, and 24.2, respectively. Therefore, eplerenone was
beneﬁcial across all risk categories. The beneﬁt derived from treatment
was greatest among those at highest risk [41].
Based on the data of these three trials, current European Society of
Cardiology (ESC) Guidelines and American College of Cardiology
(ACC)/American Heart Association (AHA) Guidelines are coherent in
strongly recommending the use of ARA with a high level of evidence
in patients with reduce LVEF and symptoms of HF (Table 3) [42–44].
Guidelineswarn that, although in clinical trials hyperkalemia andwors-
ening renal function were uncommon, they may occur more frequently
in ordinary clinical practice, especially in the elderly. Therefore, an im-
portant limitation of the use of MRA is represented by an impaired
renal function (i.e. serum creatinine is greater than 2.5 mg/dL in men
or greater than 2.0 mg/dL in women or estimated glomerular ﬁltration
rate b30 mL/min/1.73 m2), and/or potassium greater than 5.0 mEq/L.
Since MRAs have been shown to reduce ﬁbrosis and remodeling
among patients with reduced LVEF [20,34,45–47], there could be a
rationale in treating even asymptomatic patients with low LVEF for
preventing the progression of chronic HF. Some small studies suggested
that MRA could be beneﬁcial among asymptomatic patients with
dilated cardiomyopathy, at least in reducing the risk of hospitalization
[48]. However, to date there is insufﬁcient evidence to recommend
MRA among asymptomatic patients and further studies (i.e. large
RCTs) are needed.
3.2. Heart failure with preserved ejection fraction (HFpEF)
Given the clear beneﬁt of aldosterone antagonists in patients with
reduce LVEF, an important question is whether there could be a role
for MRA in patients with HF and preserved ejection fraction (HFpEF).
HFpEF is deﬁned as the clinical syndrome of HF, but with preserved
systolic function and abnormalities in diastolic function. Patients with
HFpEF have a slightly lower mortality than patients with reduced
LVEF [49], however absolute mortality is still high in these patients
(i.e. 12–13%/year) highlighting the need for a treatment to improve
prognosis. No treatment has yet been shown, convincingly, to reduce
morbidity and mortality in these patients and MRAs represent a prom-
ising class of drugs.
Various physiologic mechanisms have been implicated in the patho-
genesis of HFpEF and diastolic dysfunction including increased passive
ventricular stiffness due to enhanced extracellular collagen deposition
and intrinsic alterations in myocyte cytoskeletal proteins [50], impaired
active myocardial relaxation related to altered myocyte calcium
handling and reduced myocardial energy reserve [1], 10,11 abnormal
ventricular–vascular coupling and pulsatile load as a consequence of
diminished aortic compliance [51], and impaired renal handling of salt
and water because of increased neurohormonal activation. Since
aldosterone is involved inmany of thesemechanisms,MRAmay be use-
ful in preventing many of the pathologic alterations in HFpEF.
Aldosterone antagonism has been shown to improve echocardio-
graphic measurements of myocardial relaxation in patients with
parossistic dyspnea and abnormal LV ﬁlling patterns [52]. A recent
meta-analysis showed that MRA treatment brought beneﬁts on early
mitral inﬂow (E) and E wave deceleration time (DT), which may serve
as surrogates for diastolic dysfunction [53]. This beneﬁt in HFpEF is
likely independent of the antihypertensive effects of these agents, be-
cause improvement in diastolic parameters have beendemonstrated in-
dependent of blood pressure effect: in a randomized, double-blinded,
placebo-controlled study of 30 hypertensive patients with HFpEF,
spironolactone therapy (25 mg/day) over 6 months improved LV relax-
ation and ﬁlling patterns independent of changes in BPwhen compared
with placebo [54]. The Aldosterone Receptor Blockade in Diastolic Heart
Failure (Aldo-DHF) trial showed the beneﬁts of spironolactone on
diastolic function in patients with HFpEF [55]. The Aldo-DHF trial was
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11E. Vizzardi et al. / IJC Heart & Vessels 3 (2014) 6–14a multicenter, randomized, double-blind, placebo-controlled trial of
422 patients with chronic NYHA class II or III symptoms, preserved
LVEF of≥50%, and echocardiographic evidence of diastolic dysfunction,
who were randomly assigned to spironolactone 25 mg once daily
(n = 213) or placebo (n= 209). Co-primary endpoints were changes
in diastolic function (E/e′) on echocardiography and maximal exercise
capacity (peak VO2) on cardiopulmonary exercise testing at 12 months.
MRA improved diastolic function (E/e′ decreased from 12.7 to 12.1 with
spironolactone and increased from 12.8 to 13.6 with placebo) but ther-
apy with spironolactone failed to improve maximal exercise capacity or
symptoms. Therefore it is not clear whether improvements of surrogate
end-point (such as diastolic function) may have clinical relevance in
patients with HFpEF.
The Treatment of Preserved Cardiac Function Heart Failure with
an Aldosterone Antagonist (TOPCAT) trial was the most recent and
the largest RCT that evaluated MRA therapy in HFpEF population. The
trial randomized 3445 patients with HF and LVEF N45% to receive
spironolactone or placebo. It was the ﬁrst trial of MRA in HFpEF
sufﬁciently powered to detect effects on morbidity and mortality [56].
Spironolactone failed to reduce the primary endpoint consisting in
the composite of CV death, hospitalization for the management of
HF, or aborted cardiac arrest (18.6% spironolactone vs. 20.4% placebo,
HR= 0.89, 95% CI 0.77–1.04, P= 0.14). However, patients randomized
to spironolactone were less likely to be hospitalized for HF compared
to those on placebo (12.0% vs. 14.2%, HR 0.83, 95% CI 0.69–0.99,
P = 0.042). There were no signiﬁcant differences between the groups
in deaths or hospitalizations from any cause. Hyperkalemia (18.7%
vs. 9.1%, P b 0.001) and renal failure, deﬁned as doubling of creatinine
N2 upper limit of normal, were both signiﬁcantly higher in the
spironolactone arm. Although the overall results of TOPCAT are nega-
tive, spironolactone is the ﬁrst agent who reduced HF hospitalization
rate in HFpEF population, with no increase in mortality. This is an
encouragingﬁnding since hospitalizations for HF represent amajor bur-
den in these patients, which impacts quality of life. Moreover a post-hoc
analysis of patients enrolled in theWestern regions suggested a poten-
tial efﬁcacy of spironolactone in reducing primary end-point (HR 0.82
(95% CI 0.69–0.98)) [57]. This ﬁnding and the reduction in HF hospital-
izations with spironolactone are hypothesis generating and deserve
further study.
3.3. Effects on ﬁbrosis, remodeling and arterial stiffening
The efﬁcacy of MRA in reducing ﬁbrosis has been ﬁrst demonstrated
in animal models. A study by Lacolley et al. on old normotensive rats
showed that cardiac collagen density and carotid collagen and elastin
densities and contents were signiﬁcantly decreased in association
with an increase of carotid distensibility in subjects after eight-week
treatment with spironolactone compared with controls [58]. The
same results were observed in a study conducted on rats in which
spironolactone was demonstrated able to prevent the perivascular/
interstitial ﬁbrosis and scarring [59]. These observations in animal
models encouraged to study MRA in humans [60]. The association be-
tween aldosterone and left ventricular remodeling has been shown
previously in a community-based sample. In 2119 participants in
the Framingham Offspring Study, the aldosterone–renin ratio was
positively associated with both concentric and eccentric left ventricular
hypertrophy [61]. A follow-up study performed in the same
community-based sample related elevated levels of pro-collagen type
III aminoterminal peptide (PIIINP), a marker of matrix synthesis, or
tissue inhibitor of matrix metalloproteinase-1 (TIMP1) for mortality
risk [15]. Several studies suggest that MRAs are effective in reducing
myocardial ﬁbrosis. Preclinical studies have shown that these changes
in extracellular matrix turnover are not solely the result of ﬁbroblast
aldosterone and MR activation, and that cardiomyocytes themselves
do participate in extracellular matrix remodeling [62]. Serum levels
of collagen markers have been proposed as noninvasive indicators of
12 E. Vizzardi et al. / IJC Heart & Vessels 3 (2014) 6–14myocardial collagen content, and they are well correlated [63]. A
subgroup analysis from the RALES trial revealed a highly signiﬁcant
decrease in the serum levels of PIIINP among patients treated with
spironolactone [34].Moreover, a sub-study of EPHESUS involving 476 pa-
tients showed that by 6 months and persisting at 9 months, procollagen
type I and III amino-terminal peptide (PINP andPIIINP) levelswere signif-
icantly lower among patients randomized to eplerenone, suggesting a
positive anti-ﬁbrotic and anti-remodeling action of eplerenone [64].
MRA therapy has been shown to prevent a progressive increase in
markers of collagen turnover and improved diastolic function also in
patients with HFpEF [65,66]. Other studies documented a substantial
regression of myocardial ﬁbrosis and a signiﬁcant amelioration of LV dia-
stolic dysfunction in patients with an elevated serummarker of myocar-
dial collagen accumulation [67]. A recentmeta-analysis further conﬁrmed
that administration ofMRA is correlatedwith a reduction in serum PIIINP
for patientswithHF ormyocardial infarction [53]. Finally, recent random-
ized controlled trial on 113 obese patients impaired early diastolic mitral
annular velocity, randomized to spironolactone 25 mg/day or placebo for
6 months, and showed signiﬁcant improvements inmyocardial deforma-
tion, peak early diastolic velocity (Em) and E/e′ with a simultaneous
decrease in PICP and PIIINP in spironolactone group [68].
Previous epidemiological studies have demonstrated that increased
pulse wave velocity (PWV), a marker of arterial stiffness, is associated
with an increased risk of cardiovascular morbidity and mortality [69,
70]. Arterial stiffening is frequent in HF patients and has a negative
impact on functional capacity and worsening of HF [71–73]. Elastic ar-
tery stiffening is due to degenerated elastic ﬁbers, increased collagenous
material, hypertrophied vascular smooth muscle layer, increased pro-
inﬂammatory cytokines and increased calcium deposition resulting in
a less compliant media layer [74]. Previous studies have revealed that
aldosterone increases the collagen content and ﬁbronectin accumula-
tion in the arterial wall [75,76]. A study by Park et al. demonstrated
that serum aldosterone is signiﬁcantly associated with central aortic
PWV in 438 hypertensive patients, suggesting a possible role for
aldosterone in developing central aortic stiffness and increased PWV
in hypertensive patients [77]. Studies on animal models showed a pos-
itive action ofMRAon arterial andmyocardialwall stiffness by reducing
ﬁbrosis [58,75,76,78]. Similar results have been showed in human sub-
jects: PWV decreased signiﬁcantly after six months spironolactone
treatment in hypertensive elderly subjects [79]. Both spironolactone
and eplerenone have been shown to decrease LVmass with a reduction
in the prevalence of hypertrophy in treated patients from 30% to 7%
[80]. These data suggest that MRA could be effective in reducing
myocardial remodeling in hypertensive subjects and may slow down
the progression from hypertensive heart disease to congestive heart
failure.
3.4. Arrhythmias
Arrhythmias are frequent among patients with HF and sudden
cardiac death (SCD) due to ventricular arrhythmias represents a major
cause of death in CHF. Aldosterone has been suggested to have pro-
arrhythmic effects and MRAs have been shown to have anti-arrhythmic
action. Particularly, among patients with HF, MRA demonstrated to
reduce the incidence of ventricular arrhythmias and SCD [81]. In both
the RALES and EPHESUS trials aldosterone blockade was associated to a
reduction of sudden death events. In the RALES trial, spironolactone
reduced the incidence of sudden death by 29% (RR 0.71, P = 0.02) [19].
In EPHESUS, eplerenone signiﬁcantly reduced sudden death by 21%
(RR 0.79, P= 0.03) [32]. Eplerenone was also associated with signiﬁcant
reductions in suddendeath and totalmortality in the early post-MI period
(ﬁrst 30 days), when patients are at the greatest risk of SCD [82]. In a
recent meta-analysis the therapy with MRA was associated with a 23%
risk reduction of sudden cardiac death among patients with LV systolic
dysfunction, with similar beneﬁts for spironolactone and eplerenone
[83]. Although the exact mechanism that underlies the anti-arrhythmicproperties of MRA is not known, many hypotheses have been proposed.
Probably MRAs suppress the arrhythmogenic effects of aldosterone
at multiple levels. First, MRAs contribute to modulation of renin–
angiotensin–aldosterone system reducing ventricular remodeling in HF
and in post-MI patients. At the tissue level, they limit potassium and
magnesium loss and reduce myocardial ﬁbrosis and hypertrophy
[84–86]. At the cellular level, MRAs suppress the combined effect of
aldosterone on select calcium and potassium currents, which prolongs
the ventricular action potential duration and lowers the threshold for
ventricular arrhythmias [81]. With whole-cell patch-clamp methods,
exposure to aldosterone for 48 h was shown to increase delayed after-
depolarizations in experimental models with cardiac overexpression of
human MR. This ﬁnding was attributed to MR-mediated ion channel re-
modeling, especially the down-regulation of FK506-binding proteins,
which regulate the ryanodine receptor macromolecular complex. The
resulting increased activity of ryanodine receptor leads to long-lasting
and broader calcium sparks and, consequently, to prolonged ventricular
repolarization [14]. Thus, one effect of MR antagonism would be to
decrease prolonged cardiomyocyte calcium sparks and potentially limit
arrhythmias through this mechanism. Moreover, MRAs reduce the re-
lease of norepinephrine from sympathetic nerve terminals enhancing
parasympathetic activity and promoting its direct reuptake into the
myocyte reducing ventricular arrhythmias [87,88].
In addition to its potential role in the prevention of ventricular
arrhythmias, aldosterone receptor antagonism has also a role in the
prevention of atrial arrhythmias. Atrial ﬁbrillation is the most common
sustained arrhythmia in congestive heart failure. In rat models
spironolactone reduces the adverse structural changes that occur in
congestive heart failure, including atrial ﬁbrosis and atrial remodeling
[89]. Eplerenone has been shown to suppress the inducibility of atrial
tachyarrhythmias in dog models [90]. Meta-analysis of several studies
demonstrates that ARBs and ACE-inhibitors are associated with less
atrial ﬁbrillation [91]. It is possible that additional blockade of the
RAAS system may also be particularly useful to prevent recurrence of
atrial ﬁbrillation after cardioversion as well [92]. In EMPHASIS-HF trial,
the incidence of new onset atrial ﬁbrillation or ﬂutter was a secondary
endpoint. A sub-analysis, which included 1794 patients without history
of atrial ﬁbrillation or ﬂutter, showed that eplerenone reduced the inci-
dence of new atrial ﬁbrillation: 25 of 911 eplerenone-treated patients
(2.7%) versus 40 of 883 patients (4.5%) in the placebo group (hazard
ratio [HR]: 0.58, P b 0.034). Background use of ACE inhibitor or ARBs
did not inﬂuence the results [93]. It has been proposed that aldosterone
receptor blockade may serve as a primary prevention agent of
sudden cardiac death in patient populations at risk, including long QT
syndrome, Brugada syndrome, and hypertrophic cardiomyopathy [94].
Despite that potential antiarrhythmic mechanisms of MRA exist and
the retrospective data from previous studies are encouraging, further
prospective studies are necessary to prove the efﬁcacy of these drugs
in preventing arrhythmias.4. Conclusions
Aldosterone receptor antagonists have been shown to be a highly ef-
ﬁcacious pharmacologic intervention in the treatment of HF patients
with reduced LVEF andmild to severe symptoms. In these patients cur-
rent evidence clearly shows that MRAs reducemorbidity andmortality.
MRAs have also several effects that prevent cardiac remodeling and
ﬁbrosis. These effects could potentially extend clinical utility of MRA
to a broader cardiovascular patient population, such as asymptomatic
patients with reduced LVEF, patients with HFpEF and patients at risk
of cardiac arrhythmias. To date, randomized clinical trials have only
evaluated the tip of the iceberg in terms of the patient population
that may beneﬁt from MRA. Results of ongoing and future prospective
studies will hopefully upgrade the clinical indications of this class of
medications.
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